Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: This study aims to compare the post-prandial curves of glucose, insulin, GLP-1, and GLP-2 among individuals with Crohn's disease (CD), obese individuals before and after bariatric surgery, and healthy controls.

Methods: This an exploratory cross-sectional study that involved five groups of patients (two groups of individuals with CD-active and inactive), bariatric patients (pre- and post-surgery, who were their own controls), and a distinct separated control group of healthy volunteers. C-reactive protein (CRP) levels and the post-prandial curves of glucose, insulin, GLP-1, and GLP-2 curves were assessed and compared.

Results: The pre-RYGB group presented significantly higher levels of CRP than the post-RYGB (p = 0.001) and the control group (p = 0.001). The inactive CD group presented a higher post-prandial GLP-1 area under the curve (AUC) than the pre-RYGB group (p = 0.009). The post-RYGB group presented significantly higher AUCs of GLP-2 than the pre-RYGB group (p < 0.0001), both inactive and active CD groups (p < 0.0001 in both situations), and the control group (p = 0.002). The pre-RYGB group presented a significantly higher AUC of glucose than the post-RYGB (p = 0.02) and both active and inactive CD groups (p = 0.019 and p = 0.046, respectively). The pre-RYGB group presented a significantly higher AUC of insulin than the control (p = 0.005) and both CD groups (p < 0.0001).

Conclusions: Obesity is associated with an inflammatory state comparable to the one observed in CD; inflammation may also be enrolled in the blockade of GLP-2. CD individuals present a more incretin-driven pattern of glucose metabolism, as a way to prevent hypoglycemia and compensate the carbohydrate malabsorption and GLP-2 blockade.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11695-017-2851-yDOI Listing

Publication Analysis

Top Keywords

glp-1 glp-2
12
pre-rygb group
12
group presented
12
presented higher
12
post-prandial glp-1
8
individuals crohn's
8
crohn's disease
8
bariatric surgery
8
post-prandial curves
8
curves glucose
8

Similar Publications

Gut Hormone Levels During Mixed Liquid Meal Test in Short Bowel Syndrome, the Possible Influence on the Intestine Adaptation.

Physiol Res

August 2025

3rd Department of Internal Medicine, Department of endocrinology and metabolism, General University Hospital in Prague, 1st Faculty of Medicine, Charles University, Prague, Czech Republic.

Short bowel syndrome (SBS) is an intestinal disorder characterized by reduced length of the gut most due to intestinal resection, resulting in malabsorption, malnutrition, and water and electrolyte disturbances. Intestinal adaptation is a long-term process in which GIT hormones, growth peptides, cytokines etc. are involved.

View Article and Find Full Text PDF

Context: Oral glucose tolerance test (OGTT) induces greater acute suppression of bone resorption than isoglycaemic intravenous glucose infusions (IIGI).

Objective: To study the separate and combined effects of the gut-derived hormones glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide 1 (GLP-1) and glucagon-like peptide 2 (GLP-2) on postprandial bone turnover.

Design: A randomized, crossover study with 6 experimental days.

View Article and Find Full Text PDF

Aim: To evaluate the effectiveness and safety of a fixed-ratio combination of insulin glargine 100 U/mL and lixisenatide (iGlarLixi) over 24 months in people with type 2 diabetes (T2D).

Methods: In this retrospective, observational study, data were collected from the Optum Market Clarity® database in the United States. People with T2D aged ≥18 years, previously treated with oral antidiabetic drugs ± basal insulin or glucagon-like peptide-1 receptor agonists, who initiated iGlarLixi between 1 January 2017 and 31 March 2020 and received ≥1 iGlarLixi prescription were included.

View Article and Find Full Text PDF

Gut Hormones and Inflammatory Bowel Disease.

Biomolecules

July 2025

Department of Biomedical Sciences and Diabetes Institute, Heritage College of Osteopathic Medicine, Ohio University, Athens, OH 45701, USA.

Obesity-driven inflammation disrupts gut barrier integrity and promotes inflammatory bowel disease (IBD). Emerging evidence highlights gut hormones-including glucagon-like peptide-1 (GLP-1), glucagon-like peptide-2 (GLP-2), glucose-dependent insulinotropic polypeptide (GIP), peptide YY (PYY), cholecystokinin (CCK), and apolipoprotein A4 (APOA4)-as key regulators of metabolism and mucosal immunity. This review outlines known mechanisms and explores therapeutic prospects in IBD.

View Article and Find Full Text PDF

Proglucagon-derived peptides represent a class of peptide hormones derived from the proglucagon precursor. These peptides, including glucagon, glucagon-like peptide 1 (GLP-1), glucagon-like peptide 2 (GLP-2) and oxyntomodulin, exert diverse effects on several aspects of human physiology, ranging from glucose, lipid and protein metabolism to appetite regulation, nutrient absorption and gastrointestinal motility. Their actions are mediated by distinct G protein-coupled receptors, influencing endocrine, neuroendocrine, and metabolic processes, and over recent decades, the proglucagon-derived peptides have emerged as central players in the management of metabolic and gastrointestinal diseases.

View Article and Find Full Text PDF